================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------
FORM 8-K
-------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
------------------------------------------------------------------
Date of report (Date of earliest event reported): NOVEMBER 8, 2004
KERYX BIOPHARMACEUTICALS, INC.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 000-30929 13-4087132
---------------------------- ------------------------ -------------------
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
750 LEXINGTON AVENUE
NEW YORK, NEW YORK 10022
----------------------------------------
(Address of Principal Executive Offices)
(212) 531-5965
----------------------------------------------------
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act.
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
|_| Pre-commencement communications pursuant to Rule 14d-2b under the Exchange
Act.
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act.
================================================================================
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On November 8, 2004, Keryx Biopharmaceuticals, Inc. ("Keryx") issued a
press release announcing results of operations for the third quarter ended
September 30, 2004. Keryx also announced that it would host a conference call on
November 9, 2004, for investors where Keryx will discuss its results of
operations and financial results. A copy of such press release is being
furnished as Exhibit 99.1 to this report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
KERYX BIOPHARMACEUTICALS, INC.
(Registrant)
Date: November 8, 2004
/S/ Ron Bentsur
By: ___________________________
Ron Bentsur
Vice President Finance and
Investor Relations
INDEX TO EXHIBITS
EXHIBIT
NUMBER DESCRIPTION
------- -----------
99.1 Press Release dated November 8, 2004.